Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 23, Number 3—March 2017

Research

Zika Virus RNA Replication and Persistence in Brain and Placental Tissue

Julu BhatnagarComments to Author , Demi B. Rabeneck, Roosecelis B. Martines, Sarah Reagan-Steiner, Yokabed Ermias, Lindsey B.C. Estetter, Tadaki Suzuki, Jana M. Ritter, M. Kelly Keating, Gillian Hale, Joy Gary, Atis Muehlenbachs, Amy J. Lambert, Robert Lanciotti, Titilope Oduyebo, Dana Meaney-Delman, Fernando Bolaños, Edgar Alberto Parra Saad, Wun-Ju Shieh, and Sherif Zaki
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Bhatnagar, D.B. Rabeneck, R.B. Martines, S. Reagan-Steiner, Y. Ermias, L.B.C. Estetter, T. Suzuki, J. Ritter, M.K. Keating, G. Hale, J. Gary, A. Muehlenbachs, T. Oduyebo, D. Meaney-Delman, W. Shieh, S.R. Zaki); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (A. Lambert, R. Lanciotti); Patología Hospital Universitario de Neiva, Neiva, Colombia (F. Bolaños); Instituto Nacional de Salud, Bogota, Colombia (E.A. Parra Saad)

Main Article

Table 4

Characteristics and laboratory findings of case-patients with adverse pregnancy outcome*

Case-patient no. Maternal travel history or residence Maternal symptom onset, gestation wk/trimester Outcome End of pregnancy, gestational age, wk/trimester Results of Zika virus testing performed on FFPE tissues
RT-PCR ISH†
81 Colombia 1/first SA 6/first Positive (placenta) Positive (placenta)
47 Honduras‡ 5/first SA ≈8/first Positive (placenta) Positive (placenta)
57 Puerto Rico‡ 5/first SA 8/firstt Positive (placenta) Positive (placenta)
56 Guatemala‡ 6/first SA 11/first Positive (placenta) Positive (placenta)
18 American Samoa 7/first SA 14/second Positive (placenta, fetal tissue) Positive (placenta, fetal tissue)
78 Colombia 7/first SA 11/first Positive (placenta) Positive (placenta)
125 Brazil 8/first SA 11/first Positive (placenta) Positive (placenta)
256 Brazil 8/first SA 13/first Positive (placenta) Negative (placenta)
79 Colombia NA/first SA 9/first Positive (placenta) Positive (placenta)
80 Mexico‡ 6/first SA 12/first Negative (placenta, cord) ND
19 Dominican Republic‡ 1/first SA 10/first Negative (placenta) ND
45 Honduras‡ 13/first ET 19/second Positive (placenta); negative umbilical cord, fetal brain, liver, lung) Positive (placenta)
76 Puerto Rico 7/first ET 9/first Positive (placenta) Negative (placenta)
28 Dominican Republic‡ NA/first ET 16/second Positive (placenta) Negative (placenta)
97 El Salvador NA/first IUFD§ 34/third Negative (placenta) ND
92 American Samoa NA/second IUFD 24/second Negative (placenta, umbilical cord, membrane) ND
556 Marshall Islands‡ 31/third IUFD 36/third Negative (placenta, umbilical cord, membrane) ND

*ET, elective termination; FFPE, formalin-fixed, paraffin-embedded; ISH, in situ hybridization; IUFD, intrauterine fetal demise; NA, not available; ND, not done; RT-PCR, reverse transcription PCR; SA, spontaneous abortion.
†ISH results include staining by both sense and antisense probes.
‡Travel history.
§With microcephaly.

Main Article

Page created: February 17, 2017
Page updated: February 17, 2017
Page reviewed: February 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external